Trial · NCT06139796
Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV
NCT06139796, Phase 1, Phase 2, Withdrawn, PENTA Foundation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV. Trials, record NCT06139796. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06139796
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV
- NCT number
- NCT06139796
- Status
- Withdrawn
- Phases
- Phase 1, Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- PENTA Foundation
- Conditions
- HIV Infections
- Interventions
- DRV/r FDC (120/20mg)
- First posted
- 2023-11-18
- Last updated
- 2026-03-05
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pharmacokinetics Darunavir | From enrollment to the end of treatment at 24 weeks | area under the concentration-time curve (AUC0-12) (Cohort A) |
| Primary | Pharmacokinetics Darunavir | From enrollment to the end of treatment at 24 weeks | area under the concentration-time curve (AUC0-24) (Cohort B) |
| Primary | Pharmacokinetics Darunavir | From enrollment to the end of treatment at 24 weeks | maximum plasma concentration (Cmax) |
| Primary | Pharmacokinetics Darunavir | From enrollment to the end of treatment at 24 weeks | 12 hours or 24 hours post dose concentrations (C12 or C24) |
| Primary | Safety events | From enrollment to the end of treatment at 24 weeks | serious adverse events (SAEs) |
| Primary | Safety events | From enrollment to the end of treatment at 24 weeks | adverse events (AEs) of Grade 3 or higher |
| Primary | Safety events | From enrollment to the end of treatment at 24 weeks | treatment related AEs |
| Primary | Safety events | From enrollment to the end of treatment at 24 weeks | AEs leading to treatment discontinuation or modification |
| Secondary | Acceptability | From enrollment to the end of treatment at 24 weeks | Questionnaire |
| Secondary | Efficacy of treatment | From enrollment to the end of treatment at 24 weeks | HIV-1 RNA \<50 c/mL and \<400 c/mL |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06139796
GET https://conductscience.org/api/trials/v1/NCT06139796/registered